Zogenix Inc. buy klostergang
Start price
27.06.17
/
50%
€12.85
Target price
29.09.17
€18.00
Performance (%)
87.24%
End price
29.09.17
€24.07
Summary
This prediction ended on 29.09.17 with a price of €24.07. The BUY prediction by klostergang for Zogenix Inc. saw massive gains of 87.24%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Zogenix Inc. | - | - | - | - |
| iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
| iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
| iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
| iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
Comments by klostergang for this prediction
In the thread Zogenix Inc. diskutieren
Zogenix an excellent long-term investment in the rare neurological disorders
klostergang stimmt am 27.06.2017 dem Sell-Crowdsentiment mit dem Kursziel 11.7€ nicht zu.
Based on the trial results, it seems that ZX008 yields superior efficacy results compared to cannabis products. It also bodes well for ZGNX that their candidate is much further along the regulatory gauntlet compared to its peers. First to market with a superior product is very promising.
For a stock that has a market cap of $300 million dollars and the author's model projecting a market cap of $900 million, the stock looks cheap.
In addition, only 18% of institutions own the stock, so if the trials yield positive results, the hedgies will
probably pile into the stock. That plus, with over 20% of the shares short, the short squeeze could be violent, and the stock could catapult. Eight institutions initiated new positions in the stock last quarter,
and seven of the eight hedge funds have impressive performance.
(Vom Mitglied beendet)